JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anand, R.
Right arrow Articles by Lindstrom, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anand, R.
Right arrow Articles by Lindstrom, J.

Vol. 287, Issue 2, 469-479, November 1998

Determinants of Channel Gating Located in the N-Terminal Extracellular Domain of Nicotinic alpha 7 Receptor1

René Anand, Mark E. Nelson, Volodymyr Gerzanich, Gregg B. Wells and Jon Lindstrom

Neuroscience Center of Excellence and Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, Louisiana 70112 (R.A.); Department of Neurosurgery, University of Maryland, MTSF, Baltimore, Maryland 21201 (V.G.); and Department of Neuroscience (M.E.N., J.L.) and Department of Pathology and Laboratory Medicine (G.B.W.), University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104-6074

We identified regions within the N-terminal extracellular domain of alpha 7 nicotinic acetylcholine receptors that affect channel gating. By single-channel analysis of alpha 7 nicotinic acetylcholine receptors currents, we show that the difference in efficacy between the two agonists acetylcholine and 1,1-dimethyl-4-phenylpiperazinium (DMPP) is due to a slower channel activation rate by DMPP. The partial efficacy of DMPP was not caused by channel block or faster desensitization of alpha 7 AChRs by DMPP. In addition, the efficacy and, by inference, the activation rate were found to be voltage dependent. Using chimeras of the two closely related subunits alpha 7 and alpha 8, we map residues that affect channel activation rate and agonist affinity to two different regions of the extracellular domain. Residues that affect channel activation rate are within the sequence 1-179, whereas residues that affect agonist affinity are within the sequence 180-208.


0022-3565/98/2872-0469$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. Criado, J. Mulet, J. A. Bernal, S. Gerber, S. Sala, and F. Sala
Mutations of a Conserved Lysine Residue in the N-Terminal Domain of {alpha}7 Nicotinic Receptors Affect Gating and Binding of Nicotinic Agonists
Mol. Pharmacol., December 1, 2005; 68(6): 1669 - 1677.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Lin, E. M. Jeanclos, M. Treuil, K.-H. Braunewell, E. D. Gundelfinger, and R. Anand
The Calcium Sensor Protein Visinin-like Protein-1 Modulates the Surface Expression and Agonist Sensitivity of the alpha 4beta 2 Nicotinic Acetylcholine Receptor
J. Biol. Chem., October 25, 2002; 277(44): 41872 - 41878.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. M. Jeanclos, L. Lin, M. W. Treuil, J. Rao, M. A. DeCoster, and R. Anand
The Chaperone Protein 14-3-3eta Interacts with the Nicotinic Acetylcholine Receptor alpha 4 Subunit. EVIDENCE FOR A DYNAMIC ROLE IN SUBUNIT STABILIZATION
J. Biol. Chem., July 20, 2001; 276(30): 28281 - 28290.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.